CLSD
Price:
$0.929
Market Cap:
$70.46M
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated i...[Read more]
Industry
Biotechnology
IPO Date
2016-06-02
Stock Exchange
NASDAQ
Ticker
CLSD
According to Clearside Biomedical, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.49. This represents a change of -10.42% compared to the average of 5.01 of the last 4 quarters.
The mean historical Current Ratio of Clearside Biomedical, Inc. over the last ten years is 5.57. The current 4.49 Current Ratio has changed 7.96% with respect to the historical average. Over the past ten years (40 quarters), CLSD's Current Ratio was at its highest in in the September 2016 quarter at 307.67. The Current Ratio was at its lowest in in the March 2015 quarter at 0.
Average
5.57
Median
4.02
Minimum
1.82
Maximum
15.46
Discovering the peaks and valleys of Clearside Biomedical, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 398.36%
Maximum Annual Current Ratio = 15.46
Minimum Annual Increase = -82.00%
Minimum Annual Current Ratio = 1.82
Year | Current Ratio | Change |
---|---|---|
2023 | 4.42 | -47.02% |
2022 | 8.34 | -8.11% |
2021 | 9.08 | 398.36% |
2020 | 1.82 | -21.22% |
2019 | 2.31 | -43.57% |
2018 | 4.10 | 47.23% |
2017 | 2.78 | -82.00% |
2016 | 15.46 | 292.31% |
2015 | 3.94 | 14.80% |
2014 | 3.43 | 16.27% |
The current Current Ratio of Clearside Biomedical, Inc. (CLSD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
7.28
5-year avg
5.20
10-year avg
5.57
Clearside Biomedical, Inc.’s Current Ratio is less than POINT Biopharma Global Inc. (9.14), less than ORIC Pharmaceuticals, Inc. (13.15), greater than Lyra Therapeutics, Inc. (3.64), less than Inhibrx Biosciences, Inc. (4.70), less than ESSA Pharma Inc. (38.64), less than Sensei Biotherapeutics, Inc. (8.84), less than NextCure, Inc. (9.07), less than Nuvation Bio Inc. (9.57), less than Graphite Bio, Inc. (11.47), less than Merrimack Pharmaceuticals, Inc. (10.78), less than Gracell Biotechnologies Inc. (7.73), less than Theseus Pharmaceuticals, Inc. (29.93), less than Monte Rosa Therapeutics, Inc. (6.03), less than Design Therapeutics, Inc. (34.61), less than Erasca, Inc. (11.00), greater than Eyenovia, Inc. (0.74), less than Alpha Tau Medical Ltd. (10.99), less than Ocular Therapeutix, Inc. (13.01), less than Tenaya Therapeutics, Inc. (5.27), less than Inozyme Pharma, Inc. (7.68), less than Generation Bio Co. (6.34), less than Kronos Bio, Inc. (8.32), less than C4 Therapeutics, Inc. (6.31), less than Edgewise Therapeutics, Inc. (26.35),
Company | Current Ratio | Market cap |
---|---|---|
9.14 | $1.33B | |
13.15 | $577.94M | |
3.64 | $11.28M | |
4.70 | $209.76M | |
38.64 | $71.43M | |
8.84 | $11.42M | |
9.07 | $24.31M | |
9.57 | $949.12M | |
11.47 | $185.19M | |
10.78 | $223.97M | |
7.73 | $989.87M | |
29.93 | $181.50M | |
6.03 | $433.13M | |
34.61 | $359.54M | |
11.00 | $726.61M | |
0.74 | $9.54M | |
10.99 | $216.07M | |
13.01 | $1.31B | |
5.27 | $131.51M | |
7.68 | $188.22M | |
6.34 | $71.47M | |
8.32 | $57.32M | |
6.31 | $273.18M | |
26.35 | $2.80B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Clearside Biomedical, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Clearside Biomedical, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Clearside Biomedical, Inc.'s Current Ratio?
How is the Current Ratio calculated for Clearside Biomedical, Inc. (CLSD)?
What is the highest Current Ratio for Clearside Biomedical, Inc. (CLSD)?
What is the 3-year average Current Ratio for Clearside Biomedical, Inc. (CLSD)?
What is the 5-year average Current Ratio for Clearside Biomedical, Inc. (CLSD)?
How does the current Current Ratio for Clearside Biomedical, Inc. (CLSD) compare to its historical average?